Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.
To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.
Trials Currently Recruiting Participants - Melanoma Committee
STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
EA6134 A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Michael B. Atkins, MD, Chair
(Sandra Lee, ScD)
EA6141 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma F. Stephen Hodi, MD,
Ahmad A. Tarhini, MD, PhD, Co-Chair
(Sandra Lee, ScD)
EA6174 A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma Brian R. Gastman, MD,
Charles C. Hsu, MD, PhD, Co-Chair
500 10/01/2018 EA6174 Resources
EA6183 A Phase II Neoadjuvant Study of Encorafenib With Binimetinib in Patients With Resectable Locoregional Metastases From Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)
Note: Trial open at a limited number of sites.
Leslie A. Fecher, MD, Chair
Anthony F. Shields, MD, Imaging Co-Chair
42 02/18/2020 EA6183 Resources
EA6192 Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Geoffrey T. Gibney, MD
(Sandra J. Lee, ScD)
150 08/27/2020 EA6192 Resources